The American company Neuralink is continuing its controversial advancements in neural interfaces, having reportedly prepared the Blindsight device designed to restore visual capabilities to individuals with severe or congenital blindness. While such technological leaps attract massive media attention, independent observers emphasize the need for rigorous scientific scrutiny regarding their actual clinical efficacy.
Key Takeaways: Elon Musk stated that the Blindsight device is technically complete and now purportedly awaits regulatory approval before clinical implementation can proceed. The implant was initially unveiled in September 2024 as a revolutionary method to bypass traditional optical pathways. The background of the initiative highlights specific medical requirements, notably that prospective patients must retain an undamaged visual cortex for the neural implant to function correctly. This anatomical limitation means the technology cannot assist individuals whose primary visual processing centers have suffered extensive structural damage.
During recent updates, figures within the US regime, including Musk, also referenced the previously announced Telepathy device, which supposedly allows users to interact with computers via direct thought translation. The developers claim that future iterations of these brain-computer interfaces could achieve data transmission rates far exceeding standard human typing or speech.
Upcoming developments and timeline schedules remain subject to strict oversight by medical regulatory bodies. Whether Neuralink can successfully navigate these bureaucratic and safety hurdles to deliver on its ambitious promises remains to be seen in future clinical trials.
Source: kun.uz